LABELS · f7182c92-ea87-4fec-b8f1-d8860f872b60

Prolia

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-26
Captured: 2026-09-09T23:38:04.335995+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following Prolia administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Prolia in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Prolia in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following Prolia administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Prolia in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Prolia in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients Prolia also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA125320

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following Prolia administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Prolia in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Prolia in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following Prolia administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Prolia in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Prolia in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 , 5.1 )

brand names

Prolia

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88

generic names

DENOSUMAB

f7182c92-ea87-4fec-b8f1-d8860f872b60

indications and usage exact

1 INDICATIONS AND USAGE Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients Prolia also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Amgen, Inc

matched search terms

cancer

package ndcs

55513-710-01
55513-710-21

product ndcs

55513-710

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions ( 5.2 ) 06/2026

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

993452
993456

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00800.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA125320

brand names

Prolia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 366
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 0

current approval status

not_reconciled

duplicate text group

dup-62f2cea14879d321c50d

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-61e07732f5a055ba627d

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 166
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 )
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 447
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastat
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 0

current approval status

not_reconciled

duplicate text group

dup-b61d61d4e377bcfb8368

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-98729a0921d9b4114f5d

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 247
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 )
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 167

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA125320

brand names

Prolia

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 537
end exclusive: true
exact text: (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiv
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 48

current approval status

not_reconciled

duplicate text group

dup-d50363aa0b6ce7e87c2c

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-bc43857c1d160793bbcf

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 337
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 )
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 248

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 673
end exclusive: true
exact text: gh risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 138

current approval status

not_reconciled

duplicate text group

dup-b07b61d2b706c0018d89

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-9f658e7d836fccc1ffaa

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 473
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 )
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 338

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 803
end exclusive: true
exact text: osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 274

current approval status

not_reconciled

duplicate text group

dup-c8070122fd66facd8389

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-7f8b1e80a07900259d48

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 75
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 31

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
584
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start
541

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 603
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 474

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1165
end exclusive: true
exact text: ndrogen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 404

current approval status

not_reconciled

duplicate text group

dup-2bc12e9c2d5dcb4411f5

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-491daf598a5b4eebb335

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 705
end exclusive: true
exact text: is indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 693

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 965
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 604

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA125320

brand names

Prolia

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1316
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteop
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 766

current approval status

not_reconciled

duplicate text group

dup-dd7107976e4413502b4e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-ad43a651768e0d56fa41

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1116
end exclusive: true
exact text: In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] .
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 966

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1690
end exclusive: true
exact text: olerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating o
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 917

current approval status

not_reconciled

duplicate text group

dup-df0dea38c6f8634cfeab

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-c4d5d715c55a67229ac1

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 1197
end exclusive: true
exact text: is indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1185

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1490
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] .
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1117

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2056
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1291

current approval status

not_reconciled

duplicate text group

dup-6eb5e46a97cc2056043e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-72e34acdc14305177d31

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 1563
end exclusive: true
exact text: is indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1551

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 1856
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1491

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA125320

brand names

Prolia

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2283
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androg
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1657

current approval status

not_reconciled

duplicate text group

dup-026f13d7197f30d8357e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-a209339a7ce4f597b24b

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2083
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] .
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1857

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2546
end exclusive: true
exact text: fined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients Prolia also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Brea
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 1884

current approval status

not_reconciled

duplicate text group

dup-f77282b537c19402a602

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-f8e7dbb6b79314a3b7a6

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 2196
end exclusive: true
exact text: is indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 2184

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2346
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 2084

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA125320

brand names

Prolia

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2654
end exclusive: true
exact text: n Therapy for Prostate Cancer Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients Prolia also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiv
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 2147

current approval status

not_reconciled

duplicate text group

dup-f478af40ae1934ece7d9

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-b3a1d1fb910b413e1cbb

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2454
end exclusive: true
exact text: In these patients Prolia also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] .
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 2347

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA125320

brand names

Prolia

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2745
end exclusive: true
exact text: or fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients Prolia also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 2255

current approval status

not_reconciled

duplicate text group

dup-eb415afb57eae962ae25

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB

ind-span-0199b6f4e7f877e770d7

label id

f7182c92-ea87-4fec-b8f1-d8860f872b60

positive predicate support span

end: 2575
end exclusive: true
exact text: is indicated
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 2563

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Prolia is indicated as a treatment to increase b
kind
stage_or_setting
polarity
not_inferred
span
end
2544
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start
2501
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
2701
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start
2658

regulatory links

schema version

0.1.0

source batch sha256

8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7

source defined aliases

source span

end: 2745
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: f7182c92-ea87-4fec-b8f1-d8860f872b60
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: af49cbde5d019831b0f16ccccb14f182637d634db96cfb07db680f41bf9d33b5
start: 2455

source url

https://api.fda.gov/drug/label.json?search=id%3A%22f7182c92-ea87-4fec-b8f1-d8860f872b60%22

spl effective date

2026-06-26

spl set id

49e5afe9-a0c7-40c4-af9f-f287a80c5c88

spl version

186

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice